See more : Hubei Kailong Chemical Group Co., Ltd. (002783.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Key Capital Corporation (KCPC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Key Capital Corporation, a leading company in the Financial – Conglomerates industry within the Financial Services sector.
- Veljan Denison Limited (VELJAN.BO) Income Statement Analysis – Financial Results
- Ingentec Corporation (4768.TWO) Income Statement Analysis – Financial Results
- PayPal Holdings, Inc. (2PP.F) Income Statement Analysis – Financial Results
- OncoTherapy Science, Inc. (4564.T) Income Statement Analysis – Financial Results
- Globe Trade Centre S.A. (GBCEY) Income Statement Analysis – Financial Results
Key Capital Corporation (KCPC)
Industry: Financial - Conglomerates
Sector: Financial Services
About Key Capital Corporation
Key Capital Corporation, a development stage company, engages in the mining and mining industry financing business worldwide. The company operates as a streaming, structured finance, and equity funder of mining projects through funding agreements for an interest in the production of mines containing gold, silver, base metals, or energy products. It is also involved in funding resource and energy projects through its online lending platform. In addition, the company, through its subsidiary, GeoGlobal Resources, Inc., engages in the exploration and production of oil and gas in three blocks in the onshore Cambay Basin, as well as the gas production testing in offshore Deen Dayal West Field in the Krishna-Godavari Basin. The company was formerly known as Elite Computer Services, Inc. and changed its name to Key Capital Corporation in April 1998. Key Capital Corporation was founded in 1996 and is headquartered in New York, New York. Key Capital Corporation operates as a subsidiary of KeyCorp.
| Metric | 2022 | 2021 | 2020 | 2019 | 2013 | 2012 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 407.88 | 92.09 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 407.88 | 92.09 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 407.88 | 92.09 |
| Cost & Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 407.88 | 92.09 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 228.49K | 236.56K | 206.30K | 171.86K | 407.88 | 92.09 |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | -407.88 | -92.09 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 0.00 | 0.00 | 0.00 | 0.00 | -407.88 | -92.09 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 0.00 | 0.00 | 0.00 | 0.00 | -407.88 | -92.09 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 0.00 | 0.00 | 20.39K | 9.94K |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 0.00 | 0.00 | 27.14K | 9.94K |
Key Capital Offers to Help India COVID Crisis with Major Aid Potential via its 24/7 Immune Supplement
Key Capital HAP-V+ Immune Supplement Reported Effective Against COVID-19, and Colds and Flu
Key Capital Launches Unique Natural Mental Health Supplement - MaxCellLife MIND
Key Capital Launches MaxCellLife.com to Market Unique Supplement and Skincare Products
Key Capital to Focus on Oral Pill Cancer Treatment Success
Key Capital Leads Oral Pill Vaccines Race with Immunitor Partnering and Strong Patenting
Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study
Key Capital Advises Urgent Global Need For COVID-19 Oral Pill Therapeutic Vaccine
Source: https://incomestatements.info
Category: Stock Reports